New Pan|Cancer CDx Added to the TruSight Oncology Test

FDA approves Illumina cancer biomarker test with two companion ...

A CDx test may identify whether a patient's tumor has a ... TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test ...

New Pan-Cancer CDx Added to the TruSight Oncology Test

A new pan-cancer companion diagnostic indication has been added to the TruSight Oncology Comprehensive test, which will help identify ...

Illumina Introduces New Pan-Cancer Companion Diagnostic to ...

Most CDx tests are specific to one type of cancer, but the NTRK ... TruSight Oncology Comprehensive is an in vitro diagnostic test that ...

Illumina Obtains CDx Pan-Cancer Indication for TruSight Test

Illumina has won a companion diagnostic indication for its TruSight Oncology Comprehensive test to be used with Bayer's Vitrakvi. ... The addition of this first ...

TruSight Oncology Test Receives FDA Approval for NTRK and RET ...

... (CDx) for 2 important cancer indications. The test is approved to identify patients with solid tumors harboring NTRK gene fusions and non ...

FDA approves Illumina cancer biomarker test with two companion ...

A CDx test may identify whether a patient's tumor has a ... TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test ...

Illumina adds new CDx indication to TruSight Oncology test

Illumina has introduced a new pan-cancer companion diagnostic, adding new indications to its TruSight Oncology (TSO) Comprehensive (EU) ...

Illumina Adds CDx Indication to European TruSight Oncology Test ...

The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's ...

Illumina Adds CDx Indication to European TruSight Oncology Test ...

The CDx pan-cancer indication will allow the ... CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection ... NEW YORK – Illumina said on ...

Illumina's IVD Biomarker Test Becomes the First FDA-approved Pan ...

Illumina Partnering with Top Pharma Companies for Further Upgrades of its CDx Tool. “The FDA approval for TruSight Oncology Comprehensive ...

Illumina's TruSight Test in EU Gets Companion Dx Indication

Illumina has added a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight Oncology (TSO) test in the EU.

P230011 - Premarket Approval (PMA) - FDA

TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test ... In addition, the test is intended to provide tumor profiling information for ...

Illumina Adds CDx Indication to European TruSight Oncology Test ...

The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi ...

News - TruSight Oncology Comprehensive - LARVOL VERI

today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test.

Illumina Launching Pan-Cancer IVD Test, Cloud-Based ...

... TruSight™ Oncology product family by adding IVD test. The tumor ... We haven't announced that yet, whether it's in addition to NovaSeq or a new ...

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx ...

... TruSight Oncology content and Myriad's myChoice CDx test. "The agreement between Myriad and Illumina combines clinically validated companion ...

TruSight Oncology Comprehensive - accessdata.fda.gov

In addition, the test is intended to provide tumor ... CDx and Tumor Profiling variants for both qualitative and quantitative analysis.

Evaluation of the TruSight Oncology 500 Assay for Routine Clinical ...

FoundationOneCDx is a single-site, panel-based, next-generation sequencing (NGS) assay using formalin-fixed, paraffin-embedded (FFPE) tumor specimens for tumor ...

Illumina introduces pan-cancer CDx - CAP TODAY

... added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow ...

Illumina gets FDA nod for TruSight Oncology Test with two CDx

TSO Comprehensive analyses RNA to detect a wide range of known and new gene fusion partners across NTRK1, NTRK2, and NTRK3 genes. In addition, ...